tesseratherapeutics.comCrawled Nov 7, 2026
The company develops non-viral delivery technology to enable targeted genomic alterations.
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a biotechnology for scientific and medical use.
Tessera Therapeutics presents preclinical data supporting its **Gene Writing™**-based programs for **in vivo sickle cell disease treatment** and **CAR-T applications** at the 68th American Society of Hematology (ASH) Annual Meeting. The company highlights three new studies demonstrating progress in its genetic medicine approach. Presentations occur during the December 12–15 event in New Orleans.
Nov 2026Tessera TherapeuticsNews article
Tessera Therapeutics names **Joseph Romanelli** as its new **President and Chief Executive Officer**. A seasoned pharmaceutical executive, Romanelli will oversee the company’s transition from platform development to building a **clinical pipeline of genetic medicines** using its **Gene Writing** technology. Tessera aims to expand its portfolio of precision genetic therapies under his leadership.
Jul 2026Tessera TherapeuticsNews article
Tessera Therapeutics secures funding from the Gates Foundation to develop **in vivo gene-writing techniques** targeting a scalable HIV cure. The grant supports multiple experimental approaches aimed at modifying cellular mechanisms to combat the virus. The company focuses on translating these methods toward clinical applications.
Mar 2026Tessera TherapeuticsNews article
Tessera Therapeutics secures FDA clearance for its **TSRA-196**, an in vivo gene-editing therapy targeting **alpha-1 antitrypsin deficiency (AATD)**. The company’s **Gene Writing™** platform enables direct genetic modification to address the rare liver disease. Tessera also receives ethics approval from Australia’s **Human Research Ethics Committee (HREC)** to initiate **Phase 1 trials**, marking progress toward clinical testing. The IND clearance allows the therapy to advance into human studies in the U.S.
Jan 2026Tessera TherapeuticsNews article
